Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer

BACKGROUND: Treatment with gemcitabine/nab-paclitaxel confers a survival benefit over gemcitabine monotherapy in patients with advanced pancreatic cancer (APC). However, such treatment can be associated with significant toxicities especially in older patients and carries practical disadvantages rela...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Therap Adv Gastroenterol
Autori principali: Rehman, Hasan, Chi, Jeffrey, Hakim, Nausheen, Goyal, Shreya Prasad, Olazagasti, Coral, Jose, Jyothi, Moriarty, Linda, Saif, Muhammad Wasif
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692343/
https://ncbi.nlm.nih.gov/pubmed/33281939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284820974912
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi